Opinions Brian Madden
Apotex HealthAPTX.TOTOP PICKAug 07, 2026
Brian MaddenOwned
N/A
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
WAIT
Looks impressive, but he likes a bit more trading history before jumping in. (Interestingly, the IPO came out just before SpaceX, and APTX has outperformed it.) Seeing amazing growth, as well as projected growth. Moving beyond generics to biosimilars (take long to be approved, not as much risk, margins tend to be higher). Expanding to US and beyond.
Largest manufacturer of conventional, specialty, and biosimilar generic drugs in Canada. Cleaner balance sheet since the IPO. Big near-term catalyst is GLP-1 market; first-mover advantage could lead it to capture 20% or more of that market. Lots of branded pharmaceuticals going off patent in Canada in next 5 years.
(Analysts’ price target is $41.24)Good-sized position in US, growing organically there as well. No dividend.